Patient distribution and outcome according to karyotype group stratified for SCT
. | . | No SCT . | . | SCT . | . | ||
|---|---|---|---|---|---|---|---|
. | n . | Alive, no. . | Dead, no. . | Alive, no. . | Dead, no. . | ||
| Normal karyotype | 20 | 7 | 1 | 10 | 2 | ||
| Monosomy 7 | 26 | 2 | 4 | 13 | 7 | ||
| Trisomy 8 or other abnormalities | 11 | 4 | 1 | 5 | 1 | ||
. | . | No SCT . | . | SCT . | . | ||
|---|---|---|---|---|---|---|---|
. | n . | Alive, no. . | Dead, no. . | Alive, no. . | Dead, no. . | ||
| Normal karyotype | 20 | 7 | 1 | 10 | 2 | ||
| Monosomy 7 | 26 | 2 | 4 | 13 | 7 | ||
| Trisomy 8 or other abnormalities | 11 | 4 | 1 | 5 | 1 | ||
SCT data for patients with available karyotype and follow-up of more than 16 months. Because median time from diagnosis to SCT was 16 months, 9 patients with a follow-up of less than 16 months were excluded from the analysis (2 patients had normal karyotype, 6 had monosomy 7, and 1 had other abnormalities).